Skip to main content

CASE REPORT article

Front. Oncol.
Sec. Cancer Immunity and Immunotherapy
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1403762
This article is part of the Research Topic Community Series in Methods in Cancer Immunity and Immunotherapy: 2023, Volume II View all articles

Etoposide, Cisplatin and Sintilimab Combined with Anlotinib in successful Treatment of Adrenocortical Carcinoma with Lung Metastasis: A Case Report

Provisionally accepted
Wenjing Niu Wenjing Niu 1Haimei Zhang Haimei Zhang 2Xuezhen Ma Xuezhen Ma 2*Hua Liang Hua Liang 2Zhongshi Qiao Zhongshi Qiao 2Zheng Wang Zheng Wang 3Lifeng Niu Lifeng Niu 4
  • 1 Shandong Second Medical University, Weifang, China
  • 2 Qingdao Central Hospital CHINA, Qingdao, Shandong Province, China
  • 3 Zhucheng People's Hospital, zhucheng, China
  • 4 School of Clinical Medicine, Binzhou Medical University,, Binzhou, China

The final, formatted version of the article will be published soon.

    Background: Adrenocortical carcinoma (ACC) is a rare malignant tumor that occurs in the adrenal cortex. It has a high degree of malignancy and comparatively poor overall prognosis. Surgery is the standard curative therapy for localized ACC patients. As well as, the combination regimen of etoposide, doxorubicin, cisplatin (EDP) plus mitotane has been considered as the standardized chemotherapy regimen for advanced ACC. However, new effective regimens are emerging for specific conditions in metastatic ACC.Case Presentation: We report a case of a 66-year-old man diagnosed with metastatic ACC who had a large left adrenal mass (110 mm*87 mm) and multiple metastases in both lungs. The patient was treated with EP and sintilimab for six cycles, anlotinib was introduced after the third cycle. Followups after the second to fourth cycles found significantly reduced lung metastases with all imaging examinations indicating Partial Response (PR) status. The patient received maintenance therapy thereafter with sintilimab plus anlotinib. Until recently, the patient's lung metastases and the left adrenal gland area mass(39mm×29mm) have disappeared and no disease progression has been observed. The progression free survival of this patient has been extended to about 31 months, in sharp contrast to a median survival time of 12 months for majority of advanced ACC. The main adverse events during treatment were appetite loss, grade I myelosuppression, revealed only grade I hypertension and grade I hypothyroidism.Conclusion: This case highlights the remarkable response of our patient's ACC to treatment with a novel combination of EP and sintilimab combined with anlotinib. Our findings suggest a safe and more effective combination therapeutic option for patients with patients with adrenocortical carcinoma.

    Keywords: Adrenocortical Carcinoma, Anlotinib, Sintilimab, case report, Etoposide, Cisplatin

    Received: 19 Mar 2024; Accepted: 25 Jul 2024.

    Copyright: © 2024 Niu, Zhang, Ma, Liang, Qiao, Wang and Niu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Xuezhen Ma, Qingdao Central Hospital CHINA, Qingdao, Shandong Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.